Back to Search
Start Over
New Topical Therapies for Psoriasis
- Source :
- American Journal of Clinical Dermatology. 23:13-24
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients' quality of life. Mild-to-moderate forms of the disease usually require long-term topical treatment, but prolonged use of corticosteroids and vitamin D analogues is limited by adverse effects. With further understanding of psoriasis pathogenesis, new molecules are emerging aiming to fulfil these clinical needs. Tapinarof, an aryl hydrocarbon receptor modulator, has completed a phase III study and demonstrated good efficacy results, even in long treatment courses, with a favourable safety profile. It additionally appears to have a promising remitting effect as patients presented with an average relapsing time of over 3 months. Roflumilast, a phosphodiesterase type 4 inhibitor, also underwent a phase III study with significant lesion improvement and notable pruritus management, and with no reported side effects. Roflumilast was evaluated as an option for intertriginous areas with good outcomes in a small sample, but larger trials are required. The Janus kinase-signal transducer and activator of transcription pathway has been targeted in recent clinical investigations with promising options, currently with brepocitinib pending phase IIb results. Ongoing preclinical studies involving interleukin-2 inhibition, RNA modulators and amygdalin analogues may lead to forthcoming clinical trials. New topical drugs are successfully emerging and future research comparing them to classical options will dictate their clinical role in the treatment of psoriasis.
- Subjects :
- Boron Compounds
Cyclopropanes
Oncology
medicine.medical_specialty
Administration, Topical
Amygdalin
Aminopyridines
Dermatology
Intertriginous
Disease
Pharmacotherapy
Piperidines
Psoriasis
Internal medicine
Nitriles
Stilbenes
medicine
Vitamin D and neurology
Humans
Adverse effect
Roflumilast
business.industry
Resorcinols
General Medicine
Bridged Bicyclo Compounds, Heterocyclic
medicine.disease
Clinical trial
MicroRNAs
Pyrimidines
Benzamides
Interleukin-2
Pyrazoles
Dermatologic Agents
Phosphodiesterase 4 Inhibitors
business
medicine.drug
Subjects
Details
- ISSN :
- 11791888 and 11750561
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- American Journal of Clinical Dermatology
- Accession number :
- edsair.doi.dedup.....e0a8ab5843be965c967b346982c624b3